(Q33574943)

English

Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

phase III clinical trial

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

object named as

Rui-Hua Xu

15

0 references

author name string

Zhong-Zhen Guan

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Jian-Ming Xu

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Rong-Cheng Luo

3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Feng-Yi Feng

4

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Li-Wei Wang

5

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Lin Shen

6

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Shi-Ying Yu

7

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Yi Ba

8

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Jun Liang

9

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Dong Wang

10

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Shu-Kui Qin

11

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Jie-Jun Wang

12

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Jing He

13

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Chuan Qi

14

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

publication date

1 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Chinese Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

682-689

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012268

21 June 2018

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012268

21 June 2018

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012268

21 June 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012268

21 June 2018

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012268

21 June 2018

Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012268

31 October 2018

Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012268

31 October 2018

Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012268

31 October 2018

Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012268

31 October 2018

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012268

31 October 2018

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012268

31 October 2018

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012268

31 October 2018

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

1 reference

https://pubmed.ncbi.nlm.nih.gov/21959045

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.5732/CJC.011.10188

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33574943&oldid=1524855461"